Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR) is a pharmaceutical company focused on developing and commercializing oral lipid-lowering medicines to treat patients with high cholesterol and related cardiovascular conditions. Founded in 2008, the company specializes in therapies targeting elevated LDL cholesterol through innovative oral agents, aiming to provide additional options for patients who require more effective lipid management.
Company News
Esperion's partner Otsuka received Japanese regulatory approval to market NEXLETOL, a non-statin cholesterol treatment, expanding the drug's global market presence in the third-largest cardiovascular prevention market.
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ: APLD) fell sharply in today’s pre-market trading after the company reported worse-than-expected third-quarter financial results. Applied Digital posted a quarterly loss of 24 cents per share, versus a year-ago loss of 10 cents per share. The company’s quarterly sales came in at $43.35 million versus expectations of $51.92 million, according to data from Benzinga ...
Mutual funds and institutional investors put cash into the market at the end of this month.
Penny stocks to watch with big news. The post Trading Penny Stocks This Week? 4 To Watch With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.